These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30654975)

  • 1. Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease.
    Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
    Leuk Res; 2019 Apr; 79():75-80. PubMed ID: 30654975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
    Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):157-161. PubMed ID: 31521818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
    Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
    Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
    Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity.
    Shi Y; Liu P; Zhou S; Yang J; Han X; He X; Zhang C; Gui L; Qin Y; Yang S; Zhao L; Yao J; Jia B; Zhang S; Sun Y; Shi Y
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e423-e429. PubMed ID: 28101911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
    Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
    Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.
    Robinson SP; Boumendil A; Finel H; Dreger P; Sureda A; Hermine O; Montoto S
    Bone Marrow Transplant; 2018 Dec; 53(12):1553-1559. PubMed ID: 29884850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.
    Hermet E; Cabrespine A; Guièze R; Garnier A; Tempescul A; Lenain P; Bouabdallah R; Vilque JP; Frayfer J; Bordessoule D; Sibon D; Janvier M; Caillot D; Biron P; Legros L; Choufi B; Drenou B; Gorin NC; Bilger K; Tamburini J; Soussain C; Brechignac S; Bay JO;
    J Geriatr Oncol; 2015 Sep; 6(5):346-52. PubMed ID: 26116168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience.
    Helbig G; Krawczyk-Kulis M; Kopinska A; Liwoch R; Kyrcz-Krzemien S
    Med Oncol; 2014 Dec; 31(12):310. PubMed ID: 25373321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
    Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party.
    Kyriakou C; Boumendil A; Finel H; Nn Norbert Schmitz ; Andersen NS; Blaise D; Chevallier P; Browne P; Malladi R; Niederwieser D; Pagliuca A; Kroschinsky F; Montoto S; Dreger P;
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):86-93. PubMed ID: 30219698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography.
    Marani C; Raiola AM; Morbelli S; Dominietto A; Ferrarazzo G; Avenoso D; Giannoni L; Varaldo R; Gualandi F; Grazia D; Lamparelli T; Bregante S; Van Lint MT; Ibatici A; Bovis F; Lemoli RM; Gobbi M; Bacigalupo A; Angelucci E
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2501-2508. PubMed ID: 30041010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
    Sun L; Li S; El-Jawahri A; Armand P; Dey BR; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; McAfee SL; Spitzer TR; Chen YB; DeFilipp Z
    Oncologist; 2018 May; 23(5):624-630. PubMed ID: 29284757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
    Waheed F; Kancherla R; Seiter K; Liu D; Qureshi Z; Hoang A; Ahmed T
    Leuk Lymphoma; 2004 Nov; 45(11):2253-9. PubMed ID: 15512814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis.
    Wudhikarn K; Johnson BM; Inwards DJ; Porrata LF; Micallef IN; Ansell SM; Hogan WJ; Paludo J; Villasboas JC; Johnston PB
    Transplant Cell Ther; 2023 Mar; 29(3):176.e1-176.e8. PubMed ID: 36563788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The limited use of autologous hematopoietic stem cell transplant for fit older patients with multiple myeloma in India: a retrospective analysis.
    Revannasiddaiah S; Nagaraju PRVMA; Palassery R; Jagadish A; Maka VV; Kilara N; Rondelli D; Devadas SK
    J Egypt Natl Canc Inst; 2022 May; 34(1):21. PubMed ID: 35570260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.
    Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M
    Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
    Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
    Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.